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Abstract
Objective
To identify biotypes in patients with newly diagnosed Parkinson disease (PD) and to test
whether these biotypes could explain interindividual differences in longitudinal progression.
Methods
In this longitudinal analysis, we use a data-driven approach clustering PD patients from the
Parkinson’s Progression Markers Initiative (n = 314, age 61.0 ± 9.5, years 34.1% female, 5 years
of follow-up). Voxel-level neuroanatomic features were estimated with deformation-based
morphometry (DBM) of T1-weighted MRI. Voxels with deformation values that were sig-
nificantly correlated (p < 0.01) with clinical scores (Movement Disorder Society–sponsored
revision of the Unified Parkinson’s Disease Rating Scale Parts I–III and total score, tremor
score, and postural instability and gait difficulty score) at baseline were selected. Then, these
neuroanatomic features were subjected to hierarchical cluster analysis. Changes in the longi-
tudinal progression and neuroanatomic pattern were compared between different biotypes.
Results
Two neuroanatomic biotypes were identified: biotype 1 (n = 114) with subcortical brain
volumes smaller than heathy controls and biotype 2 (n = 200) with subcortical brain volumes
larger than heathy controls. Biotype 1 had more severe motor impairment, autonomic dys-
function, and much worse REM sleep behavior disorder than biotype 2 at baseline. Although
disease durations at the initial visit and follow-up were similar between biotypes, patients with
PD with smaller subcortical brain volume had poorer prognosis, with more rapid decline in
several clinical domains and in dopamine functional neuroimaging over an average of 5 years.
Conclusion
Robust neuroanatomic biotypes exist in PD with distinct clinical and neuroanatomic patterns.
These biotypes can be detected at diagnosis and predict the course of longitudinal progression,
which should benefit trial design and evaluation.
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Patients with Parkinson disease (PD) present heterogeneous
motor and nonmotor clinical manifestations and have a variable
prognosis.1,2 Although the diagnosis of PD is dependent on the
presence of tremor, bradykinesia, and rigidity, some nonmotor
phenomena—e.g., REM sleep behavior disorder (RBD),
hyposmia, and depression—can precede motor deficits by
several years. Conversely, as the disease progresses, nonmotor
problems such as autonomic disturbances, sleep disorders, and
cognitive impairment can dominate the clinical picture in some
patients.1 Recent evidence suggests that PD may have several
biotypes,3–9 but their identity and neurobiological basis remain
poorly understood.2 Assuming that homogeneous groups of
patients are more likely to share pathologic features, recogni-
tion of different subcategories of patients with PD may be key
to better understanding underlying biological mechanisms,
predicting disease profile and progression, and eventually de-
signing more efficient personalized clinical trials.2,3
Subtypes of PD have previously been defined mainly according
to clinical symptoms and demographic characteristics.3–8
However, cluster results are only as good as the data that un-
derpin them, and the depths of phenotypic information used by
these studies were variable, resulting in quite heterogeneous
and controversial clusters.2 In addition, these clinical data-
driven PD subtype classification systems may suffer from lack
reproducibility.10 An alternative to subtyping patients with PD
on the basis of co-occurring clinical symptoms is to identify
neuroanatomic biotypes by clustering patients according to
shared neuroanatomic signatures, which can objectively cap-
ture different aspects of patient characteristics. Studying brain
neuroanatomic patterns of PD provides an opportunity to ex-
amine biological heterogeneity in vivo.11 Data-driven methods
provide an unbiased approach to detect groups of patients with
similar profiles across multiple neuroanatomic feature dimen-
sions and thus may yield a more refined description of het-
erogeneity in PD. T1-weighted MRI is an especially suitable
modality to describe brain anatomy with high resolution and to
quantify regional brain volumes.12 Brain volume may mediate
brain reserve, which promotes the resilience of large-scale brain
networks and helps maintain normal function in the face of
neurodegeneration.13–16 Previous studies have shown that sub-
cortical volume loss reflects clinical measures of disease severity
and is related to the development of cognitive impairment.17–21
These studies raise the intriguing possibility that T1-weighted
MRI measures of brain volume could be leveraged to identify
biotypes of PD. Critically, such PD biotypes defined by brain
volume at diagnosis may predict disease progression, which may
be advantageous in helping to determine prognosis and to
identify subgroups for clinical trials. Cluster analysis in non-
demented PDwith limited sampling of patients showed different
PD cortical thinning subtypes.22 These PD subtypes also showed
different cortical thinning progression over time, but the differ-
ence between motor symptoms and the rates of disease pro-
gression of the different subtypes was not reported. Severity and
rate of disease progression are an important issue in PD thera-
peutics, and identifying progression biotypes of PD at diagnosis
with the use of neuroanatomic patterns may be one way to
address heterogeneity in PD.
In this study, we used data-driven clustering approaches to
identify neuroanatomic biotypes in patients with early PD in the
Parkinson’s Progression Markers Initiative (PPMI; ppmi-info.
org) database23 according to the neuroanatomic pattern derived
by deformation-basedmorphometry (DBM).24DBM is based on
nonlinear and intensity-based registration procedures that spa-
tially normalize the entire brain to a standard template.24 DBM
does not assume the distributions of gray matter or white matter
and preserves the entirety of the MRI data. PD involves axonal
degeneration and neuronal cell death, with the latter being
indexed by gray matter atrophy, which is a relatively late event in
the pathogenesis of PD.25 Moreover, neurodegeneration in PD
initially preferentially affects subcortical regions through a pur-
ported disease-spreading process.26 A particularly strong aspect of
the DBM method is that it enables the detection of subcortical
neuroanatomic features,27 and previous studies have shown that
DBM can detect morphologic tissue changes in patients with
early-stage PD.19 Therefore, DBM is particularly suitable for PD
biotype discovery compared to cortical thinning patterns and
voxel-based morphometry. We hypothesize that if heterogeneity
in clinical symptoms reflects true neuroanatomic biotypes of PD,
then such neuroanatomic biotypes should be detectable in early
disease and might predict the type of symptoms or disease pro-
gression that a patient will develop. The aims of our study were
(1) to identify biotypes of PD with cluster analysis based on a
baseline neuroimaging dataset; (2) to introduce a practical clinical
typing method, which assigns individual patients to their biotype;
and (3) to compare the behavioral assessments and rate of disease
progression between different PD biotypes.
Methods
Standard protocol approvals, registrations,
and patient consents
The study was approved by the institutional review board at
each PPMI site. Written informed consent for research was
obtained from all participants in the study.
Glossary
DAT = dopamine transporter; DBM = deformation-based morphometry; FDR = false discovery rate; MDS-UPDRS =
Movement Disorder Society–sponsored revision of the Unified Parkinson’s Disease Rating Scale; PD = Parkinson disease;
PIGD = postural instability and gait disorder; PPMI = Parkinson’s Progression Markers Initiative; RBD = REM sleep behavior
disorder.
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Overall design
A flowchart of the analysis is shown in figure 1. We began by
designing and implementing a preprocessing procedure to
control for site- and age-related effects in a multisite dataset
that comprised structural MRI scans for 457 participants (n
= 314 patients with PD, n = 143 healthy controls). A graphic
summary of the participants selection is shown in data
available from Dryad (figure e-1, doi.org/10.5061/dryad.
xsj3tx9bf). Patients and controls were matched for age and
sex. DBM was used to detect the volume of each voxel
compared to the template brain.24 Next, to select features for
use in clustering, we used Spearman rank correlation analysis
to identify a low-dimensional representation of neuroana-
tomic features that were associated with baseline clinical
symptoms within patients with PD, including Movement
Disorder Society–sponsored revision of the Unified Par-
kinson’s Disease Rating Scale (MDS-UPDRS) Parts I, II, III,
tremor, and postural instability and gait disorder (PIGD)
scores. To capture more neuroanatomic features related to
PD, correlations were not corrected for multiple compari-
sons, but the dimensions of selected features were further
reduced by principal components analysis. Then, hierarchi-
cal clustering was used to discover clusters of patients
according to the principal components. Finally, to validate
the clustering results, we investigated differences in follow-
up clinical symptoms and neuroanatomic patterns between
subgroups of patients, and we investigated the extent to
which the analysis could reliably discriminate between dif-
ferent subgroups of patients using a pattern classification
approach.
Study setting and patients
The PPMI (ppmi-info.org) is a landmark observational,
longitudinal database consisting of neuroimaging, biological
tests, and clinical and behavioral assessments in >400 pa-
tients with de novo PD.23 All patients underwent dopamine
transporter (DAT) imaging, and the diagnosis was con-
firmed by the DAT deficit. All clinical features were reas-
sessed annually over 5 years so that markers of disease
progression could be discerned. The neuroimaging data and
extensive longitudinal clinical information provide an un-
precedented opportunity to identify the neuroanatomic
biotypes of PD and the longitudinal assessment of PD pro-
gression of different biotypes in patients with de novo PD.
The clinical and behavioral assessments have been described
extensively elsewhere.
Recruitment criteria included age >30 years, PD diagnosis
within the last 2 years, baseline Hoehn and Yahr stage I to II,
and no anticipated need for symptomatic treatment within 6
months of baseline.23 Clinical assessments were performed at
baseline, at 3-months interval during the first year of partici-
pation, and then every 6 months thereafter (see data available
from Dryad, table e-1, doi.org/10.5061/dryad.xsj3tx9bf).
Data from the PPMI database were obtained in May 2018 in
compliance with the PPMI Data Use Agreement.
Baseline and clinical assessments
A comprehensive set of clinical assessments were evaluated in
PPMI. We focused on clinical features that capture major PD
symptoms, including both motor and nonmotor symptoms,
in line with previous studies.3,7,28,29 Details of clinical as-
sessments used in this study are presented in PPMI (ppmi-
info.org/wp-content/uploads/2010/04/PPMI-General-Op-
erations-Manual.pdf). Derived variable definitions and score
calculations are available in the PPMI (in the Study_Docs). A
list of abbreviations of clinical assessments is given in data
available from Dryad (table e-2, doi.org/10.5061/dryad.
xsj3tx9bf). Features captured include the following:
1. Demographics: age, sex, race, symptom duration, and
education level.
2. Blood biomarkers: biochemical tests.
3. Motor: MDS-UPDRS Parts I through III,30 tremor/PIGD
motor phenotype, PIGD, tremor subscale, and Schwab-
England activities of daily living scores.
4. Cognitive testing: cognitive function (age/education
adjusted Montreal Cognitive Assessment total score)31
and neuropsychological variables, including visuospatial
and visuoperceptual functions (Benton Judgment of Line
Orientation),32 cognition performance (Symbol Digit
Modalities Test),33 verbal learning and memory (Hopkins
Verbal Learning Test for total recall, delayed recall,
retention, and recognition-discrimination),34 semantic
memory (Semantic Verbal Fluency test),34 and working
memory capacity (letter-number sequencing).35
5. Autonomic testing: autonomic dysfunction (Scales for
Outcomes in Parkinson’s Disease–Autonomic total score
and its subscores: cardiovascular, constipation, orofacial,
thermoregulatory, sexual, pupillomotor, and urinary).36
6. Sleep disorders: RBD (RBD Screening Questionnaire
score),37 average sleep propensity in daily life (Epworth
Sleepiness Scale score).38
7. Neurobehavior: depression (Geriatric Depression Scale
score),39 trait and state anxiety (State-Trait Anxiety
Inventory score),29 and impulse control disorders and
related disorders (Questionnaire for Impulsive-
Compulsive Disorders in Parkinson’s Disease score).40
8. Olfactory testing: impaired olfaction (age/sex adjusted
University of Pennsylvania Smell Identification Test
score).41
9. Physical activity: Physical Activity Scale of the Elderly.42
Three activity categories were assessed: leisure, household
chores, and work/volunteering.
CSF and SPECT biomarkers
A lumbar puncture was conducted for all participants for the
collection of CSF. β-Amyloid1–42, phosphorylated tau, and
total tau protein were measured by INNO-BIA AlzBio3 im-
munoassay (Innogenetics Inc, Ghent, Belgium), and α-synu-
clein concentration was measured by ELISA. SPECT with the
DAT tracer 123I-ioflupane was acquired at baseline and follow-
up visits.23
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Imaging processing
T1-weighted MRI scan acquisition parameters are detailed
elsewhere (ppmi-info.org/wp-content/uploads/2017/06/
PPMI-MRI-Operations-Manual-V7.pdf).
The T1-weighted MRI images were preprocessed with the
Computational Anatomy Toolbox (CAT 12) (dbm.neuro.
uni-jena.de/cat12/), which is an extension of SPM12 to
provide computational anatomy. All these images were cor-
rected for bias, noise, and intensity and linearly and then
nonlinearly registered to the Montreal Neurological Institute
152-2009c template. Then the DBM (i.e., the determinant of
the jacobian transformation matrix) maps were calculated to
estimate the local volume in each voxel (DBM values). Raw
images of lower quality (CAT image quality rating <75%)
were excluded. The rest images were further visually checked.
Figure 1 Schematic overview of the design of this study
DBM = deformation-based morphometry; PCA = principal component analysis; UPDRS = Unified Parkinson’s Disease Rating Scale.
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Finally, the obtained preprocessed volume-based DBM data
from 314 patients with PD and 145 healthy controls were
smoothed with an 8-mm full width at half-maximum.
For volumetric analysis, FreeSurfer version 5.3 was used to
derive measures of the volume of subcortical nuclei. This is a
well-documented and freely available software.12
Voxel-level association study and clustering
We reasoned that a low-dimensional representation of a subset
of neuroanatomic features would best characterize biologically
meaningful PD biotypes, similar to the atrophy subtypes
detected in prodromal Alzheimer disease.11 Therefore, to select
a set of neuroanatomic features for use in clustering, we used
Spearman rank correlation analysis to identify features that
were significantly correlated (p < 0.01) with clinical scores
(baseline value): theMDS-UPDRS Parts I to III, UPDRS total,
tremor, and PIGD scores. Confounding factors such as age, sex,
years of education, race (categorized as white or other), and site
effect were regressed out before feature selection.
To further exclude undesired background noise, principal
component analysis was used to extract a lower-dimensional
component space of the selected features (79 principal
components were used capturing 90% of the variance). Then
we used hierarchical clustering to assign participants to
nested subgroups with similar pattern. We calculated a
similarity matrix describing the correlation distance between
every pair of participants, and then we used the Ward min-
imum variance method to iteratively link pairs of participants
in closest proximity, forming progressively larger clusters in
a hierarchical tree. Calinski-Harabasz criterion values were
used to estimate the optimal number of clusters, and the
result suggested 2 clusters as the best choice (see data
available from Dryad, figure e-2, doi.org/10.5061/dryad.
xsj3tx9bf). Furthermore, to validate the clustering, we also
clustered data using k-means clustering. The Cohen κ
agreement rate between hierarchical clustering and k-means
clustering was 0.68, which is in the substantial range, sug-
gesting that the patterns identified by the 2 different clus-
tering methods were similar (see data available from Dryad,
figure e-3).
Classification
To further test the clinical relevance of the identified neuro-
anatomic features as diagnostic features of biotypes, we ap-
plied a support vector machine to test how well this could
discriminate these 2 biotypes, that is, classify individuals into 1
of these 2 subgroups. A 10-fold cross-validation strategy was
used to estimate its accuracy, sensitivity, and specificity. The
details of classification are depicted in data available from
Dryad (figure e-4, doi.org/10.5061/dryad.xsj3tx9bf).
Statistical analyses
Demographics and clinical variables
The t test was used to determine the statistical significance of
continuous demographic and clinical variables after the
removal of confounding variables: age, sex, years of education,
race (categorized as white or other), and site effect. The χ2 test
was used to test the significance of categorical demographic
variables and phenotype variables. Statistical significance was
established at p < 0.05 (false discovery rate [FDR] correc-
tion), and the values were reported as mean (SD) for each
demographic and clinical variable. Missing data were not in-
cluded in all analysis.
Linear mixed model fitting for disease progression
rates
We estimated rates of progression for each patient with 5
years of follow-up. Linear mixed models were used to evaluate
baseline and disease progression rates over time in patients
classified in the subtypes using the lme4 package in R.43 Sex,
age, sites, race, time from baseline (months), biotype, and
their interaction were included as fixed effects. Participant
intercepts and slopes (rates of progression) were modeled as
random effects.
Data availability
All deidentified clinical and imaging data are available on the
PPMI website (ppmi-info.org) and from the corresponding
author on reasonable request.
Results
Baseline dataset characteristics
A total of 314 early patients with PD were included in this
study consisting of 207 (65.9%) men and 107 (34.1%)
women. On average, these patients with PD were 61.0 ± 9.5
years of age with a disease duration (date of enrollment minus
the date of diagnosis) of 6.9 ± 6.8 months at baseline. The
mean MDS-UPDRS Parts I through III scores were 5.6 ± 4.0,
5.9 ± 4.2, and 20.7 ± 8.7. Clinical, biological, and cognitive
characteristics of early patients with PD and matched healthy
controls are given in table 1.
Neuroanatomic features associated with the
symptoms of PD
Figure 2 shows the correlation analysis between deformation
values and baseline clinical scores. We found that a number of
neuroanatomic features correlated with UPDRS scores, in-
cluding areas spanning the caudate, putamen, thalamus, hip-
pocampus, supplementary motor area, and orbital frontal gyrus
(figure 2). These areas are consistent with previous findings
that subcortical volume loss correlates with motor symptom
severity.18 This empirical, data-driven approach to feature se-
lection identified 23,213 voxelDBMvalues that were correlated
with at least 1 baseline clinical score (figure 2).
Brain neuroanatomic patterns define 2
PD biotypes
We then tested whether these neuroanatomic feature sets
tended to cluster in patient subgroups. As illustrated in figure
3 and data available from Dryad (figure e-3, doi.org/10.5061/
dryad.xsj3tx9bf), the cluster analysis revealed 2 distinct
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Table 1 Demographic, clinical, and imaging characteristics of controls and PD biotype groups
Demography
Biotype 1 PD Biotype 2 PD t Value p Value
Baseline D (t2 2 t1) Baseline D (t2 2 t1) Baseline D (t2 2 t1) Baseline D (t2 2 t1)
Age at onset, y 61.6 (8.6) 60.7 (10) −0.697 0.691
Male sex, n (%) 76 (0.7) 131 (0.7) 0.044 0.901
Education history, y 15.6 (2.8) 15.5 (3.2) −1.298 0.47
White race, n (%) 106 (0.9) 187 (0.9) 0.044 0.901
Symptoms duration, mo 7.3 (7.5) 6.7 (6.3) −0.935 0.562
UPDRS total score 33.92
(13.9)
23.7 (20.8) 30.86
(12.6)
13.9 (17.5) −2.44 −2.00 0.147 0.178
Motor symptoms and signs
UPDRS Part II score 6.3 (4.36) 7.6 (6.5) 5.63 (4.11) 3.7 (5.3) −1.39 −3.06 0.455 0.029
UPDRS Part III score 21.14
(8.94)
10.7 (14.4) 20.11
(8.63)
7.1 (11.8) −1.52 −1.3 0.39 0.38
Tremor score 0.46 (0.27) 0.10 (0.40) 0.49 (0.31) 0 (0.4) 0.68 −0.46 0.692 0.876
PIGD score 0.24 (0.24) 0.04 (0.60) 0.22 (0.21) 0.2 (0.3) −1.11 −3.29 0.559 0.02
Schwab-England score 92.68
(5.92)
−11.1 (13) 93.95
(5.46)
−7.1 (9.3) 2.46 2.61 0.147 0.049
Tremor/PIGD phenotype, n (%) 0.347
Tremor dominant 76 (67) 144 (72)
PIGD dominant 17 (15) 36 (18)
Intermediate 21 (18) 20 (10)
Nonmotor symptoms and
signs
UPDRS Part I score 6.48 (4.4) 5.4 (5.1) 5.12 (3.62) 3.2 (5) −3.34 −1.50 0.017 0.34
RBD Screening
Questionnaire
score
5.07 (2.99) 0.93 (2.85) 3.69 (2.3) 0.89 (3.08) −4.31 −0.28 0.001 0.903
Epworth Sleepiness Scale
score
6.1 (3.4) 2.86 (4.86) 5.8 (3.6) 1.25 (4.08) −0.86 −2.30 0.585 0.085
Cognitive function
MoCA (adjusted) score 27.12 (2.1) −1.41 (4.66) 27.48 (2.1) −0.07 (2.59) 1.06 2.95 0.559 0.031
Benton Judgment of Line
Orientation score
12.5 (2.2) −0.96 (2.51) 13 (2) −0.45 (2.09) 2.19 1.45 0.147 0.34
HVLT immediate total
recall
score
24.7 (5.4) −1.71 (5.82) 24.5 (4.7) 0.75 (5.52) −0.97 2.84 0.562 0.049
HVLT discrimination
recognition score
10.3 (1.6) 0.41 (1.99) 10.3 (1.5) 0.66 (2.11) 0.23 0.94 0.901 0.595
HVLT score 0.86 (0.19) 0.008 (0.316) 0.87 (0.19) 0.02 (0.25) 0.09 0.5 0.948 0.876
Letter-number
sequencing
score
10.4 (2.6) −1.19 (2.66) 10.8 (2.7) −0.53 (2.55) 0.63 1.44 0.698 0.34
Semantic fluency
score
47.4 (11) −1.5 (10.79) 49.1 (10.9) 0.71 (10.46) 1.15 1.40 0.54 0.34
Symbol digit modalities
score
40.7 (9.1) −4.77 (10.89) 42.4 (9.6) −1.811 (9.43) 1.26 1.89 0.473 0.204
Continued
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Table 1 Demographic, clinical, and imaging characteristics of controls and PD biotype groups (continued)
Demography
Biotype 1 PD Biotype 2 PD t Value p Value
Baseline D (t2 2 t1) Baseline D (t2 2 t1) Baseline D (t2 2 t1) Baseline D (t2 2 t1)
SCOPA–Autonomic
questionnaire score
Gastrointestinal 2.38 (2.02) 2.31 (2.19) 2 (2.1) 1.48 (2.54) −1.32 −2.62 0.47 0.049
Urinary question 5.14 (5.55) 1.47 (9.15) 3.97 (2.51) 1.19 (2.6) −2.31 −0.19 0.147 0.903
Cardiovascular 0.61 (1.03) 0.44 (1.33) 0.36 (0.61) 0.40 (1.06) −2.61 −0.29 0.135 0.903
Thermoregulatory 1.24 (1.54) 0.97 (1.87) 1.09 (1.3) 0.66 (1.62) −0.94 −1.17 0.562 0.453
Pupillomotor 0.45 (0.72) 0.21 (0.87) 0.39 (0.68) 0.24 (0.67) −0.64 0.19 0.698 0.903
Sexual 4.7 (6.4) 1.65 (6.87) 3.2 (5.7) 1.8117 (6.68) −2.25 −0.06 0.147 0.95
Total score 14.5 (10.3) 7.27 (13.36) 11.0 (7.6) 5.79 (8.99) −3.35 −0.99 0.017 0.591
Geriatric Depression Scale
score
2.6 (2.5) 0.5 (2.48) 2.1 (2.2) 0.68 (2.86) −2.15 0.31 0.147 0.903
STAI score 33.3 (9.8) 1.23 (8.62) 31.5 (9.1) 0.94 (8.64) −1.84 −0.22 0.315 0.903
STAI state subscore 34.1 (10.7) −0.043 (9.51) 32.1 (9.8) −0.68 (10.52) −1.57 −0.6 0.381 0.876
Impulse control disorders
(QUIP scores)
GMB 0.02 (0.13) 0.029 (0.168) 0.01 (0.07) −0.01 (0.09) −1.03 −1.51 0.559 0.34
Sex 0.04 (0.21) 0.09 (0.3) 0.02 (0.12) 0.04 (0.27) −1.6 −0.45 0.371 0.876
Eat 0.05 (0.22) 0.03 (0.34) 0.01 (0.1) 0.041 (0.24) −2.22 0.42 0.147 0.876
Buy 0.02 (0.13) 0.03 (0.17) 0.01 (0.07) −0.01 (0.09) −1.03 −1.51 0.559 0.34
Current short 0.28 (0.73) 0.17 (0.99) 0.17 (0.48) 0.11 (0.79) −1.61 −0.14 0.371 0.917
Other 0.15 (0.45) 0 (0.64) 0.13 (0.38) 0.04 (0.57) −0.34 0.47 0.868 0.876
Olfaction UPSIT score
percentile
21.3 (8.80) 23 (1.30) 1.28 0.47
Brain imaging
Right caudate 2 (0.69) 1.97 (0.51) −0.33 0.868
Left caudate 1.92 (0.68) 2.00 (0.52) 1.35 0.47
Right putamen 0.85 (0.39) 0.83 (0.34) 0.10 0.948
Left putamen 0.77 (0.37) 0.82 (0.34) 1.72 0.347
CSF biomarkers
α-Synuclein 1,431.02
(564.96)
1,506.34
(689.83)
0.88 0.583
Aβ42 880.5
(322.85)
908.31
(429.08)
0.42 0.848
T-tau 165.12
(53.4)
169.31
(57.83)
0.49 0.805
P-tau 14.35
(4.76)
15 (5.45) 0.79 0.628
T-tau/Aβ42 0.203
(0.095)
0.203
(0.101)
0.03 0.976
P-tau/Aβ42 0.017
(0.01)
0.018
(0.01)
0.39 0.859
Continued
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clusters of patients with PD, with similar disease duration (p =
0.35, table 1). These 2 clusters comprised 36.31% (114 pa-
tients) and 63.69% (200 patients) of the 314 patients with
PD. Table 1 shows the demographic characteristics of the 2
biotype groups. There was no significant difference in age, sex,
education, symptom duration, or ratio of PIGD- and tremor-
dominant patients between the 2 biotype groups (table 1 and
data available from Dryad, table e-3).
Neuroanatomic pattern of the 2 biotypes
To illustrate the neuroanatomic pattern in the different PD
biotypes, the DBM values of the 2 biotypes were compared
with those of controls. Compared to normal controls, indi-
viduals with both biotypes showed significant differences in
subcortical regions. Figure 4 shows the comparison between
each biotype and healthy controls (p < 0.005, FDR
correction).
Those with biotype 1 had pronounced differences com-
pared to normal controls in almost the whole brain, in-
dicating more severe atrophy in brain areas in early PD.
Those with biotype 2 had predominant differences in the
subcortical regions. In addition, we found other distinct
patterns that differentiated the 2 biotypes. For example,
compared to controls, DBM values in the putamen, cau-
date, pallidum, lingual gyrus, temporal cortex, insula,
amygdala, hippocampus, and orbital frontal cortex, which
regulate motor-related, cognitive, and emotion-related
behavior, were significantly lower in patients with biotype
1, which were characterized in part by increased motor and
nonmotor symptom scores. In contrast, patients with
biotype 2 had significantly higher DBM values in the
brainstem, putamen, caudate, occipital lobe, lingual gyrus,
olfactory, posterior cingulate cortex, and white matter
areas compared to controls. Additional volumetric analy-
ses with FreeSurfer showed that patients with biotype 1
had significantly lower subcortical volumes within the
thalamus, caudate, putamen, pallidum, accumbens, amyg-
dala, and hippocampus (p < 0.05, FDR correction)
compared to patients with biotype 2 (see data available
from Dryad, table e-4, doi.org/10.5061/dryad.xsj3tx9bf).
Neuroanatomic patterns for diagnosing
PD biotypes
We reasoned that clustering could be used for training the
classifiers for the diagnosis of PD biotypes solely on the basis
of structural MRI measures. To this end, we trained classifiers
for predicting the PD biotype in individual patients. Ten-fold
cross-validation was used to assess performance and signifi-
cance. Support vector machine classifiers (using gaussian
kernel functions) yielded overall accuracy rates of 84.1%
(sensitivity 0.71, specificity 0.89, area under the curve 0.90,
data available from Dryad, figure e-6, doi.org/10.5061/dryad.
xsj3tx9bf) for the clusters characterized above.
Baseline differences in symptoms
between biotypes
Table 1 shows that at baseline patients with biotype 1 had
worse mentation, behavior, and mood (higher MDS-UPDRS
Part I score) and very much worse RBD Screening Ques-
tionnaire score than those with biotype 2. There was also
evidence of more severe autonomic function in biotype 1
(Scales for Outcomes in Parkinson’s Disease total score)
(table 1).
Disease progression in the PD biotypes
The PPMI patients were followed up for 5 years. The sample
size of the progression analysis is shown in data available from
Dryad (table e-1, doi.org/10.5061/dryad.xsj3tx9bf). Results
from a linear mixed model showed that the patients with
biotype 1 had significantly greater progression in all MDS-
UPDRS scores, with the exception of the tremor score (figure
5 and table 2). In addition, those with biotype 1 tended to
develop more severe cognitive impairment (Hopkins Verbal
Learning Test immediate total recall, letter-number se-
quencing, and Symbol Digit Modalities) (table 2 and data
available from Dryad, figure e- 8). More rapid progression
could also be seen in the patients with biotype 1 in activities of
Table 1 Demographic, clinical, and imaging characteristics of controls and PD biotype groups (continued)
Demography
Biotype 1 PD Biotype 2 PD t Value p Value
Baseline D (t2 2 t1) Baseline D (t2 2 t1) Baseline D (t2 2 t1) Baseline D (t2 2 t1)
P-tau/T-tau 0.08 (0.01) 0.09 (0.01) 0.93 0.562
Aβ42/α-synuclein 0.65 (0.19) 0.64 (0.23) −0.30 0.878
T-tau/α-synuclein 0.12 (0.03) 0.12 (0.03) −0.96 0.562
P-tau/α-synuclein 0.01
(0.003)
0.01
(0.002)
−0.18 0.905
Abbreviations: Aβ = β-amyloid; HVLT = Hopkins Verbal Learning Test; MoCA = Montreal Cognitive Assessment; P-tau = phosphorylated tau; PD = Parkinson
disease; PIGD = postural instability and gait disorder; QUIP = Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease; RBD = REM sleep
behavior disorder; SCOPA = Scales for Outcomes in Parkinson’s Disease; STAI = State-Trait Anxiety Inventory; T-tau = total tau; UPDRS = Unified Parkinson’s
Disease Rating Scale; UPSIT = University of Pennsylvania Smell Identification Test.
The t values and p values are for the comparison between patients with biotype 1 and biotype 2 PD. Baseline scores are presented, as well as the change over
follow-up in the case of clinical measures, given as D (t2 − t1). Here t1 is score at baseline and t2 is the score after 5 years follow-up. All values in parentheses
are SDs unless otherwise specified. The p values are false discovery rate corrected for multiple comparisons. Significant: p < 0.05.
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daily living (Schwab-England activities of daily living) (table 2
and data available from Dryad, figure e-7).
On dopaminergic SPECT scanning, patients with biotype
1 had worse denervation of both left caudate and left
putamen after an average of 4 years of follow-up. The right
caudate and right putamen showed no significant differ-
ence in denervation between the 2 biotypes (see data
available from Dryad, figure e-13, doi.org/10.5061/dryad.
xsj3tx9bf).
Figure 2 Correlation between DBM values and symptom scores
Warm color indicates a positive correlation between symptom scores and deformation-based morphometry (DBM) values; cold color indicates a negative
correlation between symptom scores and DBM values. (A) Correlation between DBM values and Movement Disorder Society–sponsored revision of the
Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part I score. (B) Correlation between DBM values and MDS-UPDRS Part II score. (C) Correlation
between DBM values and MDS-UPDRS III score. (D) Correlation between DBM values and MDS-UPDRS total score. (E) Correlation between DBM values and
tremor score. (F) Correlation between DBM values and postural instability and gait disorder (PIGD) score. In total, 8,855, 2,826, 4,201, 6,064, 6,994, and 1,380
deformation values correlated with UPDRS Part I, UPDRS Part II, UPDRS Part III, total UPDRS, PIGD, and tremor scores, respectively (p < 0.01, uncorrected).
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To summarize, patients with biotype 1 had higher baseline
MDS-UPDRS Part I score, worse baseline sleep problems and
autonomic dysfunction, and faster progression of most motor
symptoms, cognitive impairment, and activities of daily living
compared to patients with biotype 2 (all p < 0.05, FDR cor-
rection) (figure 5 and tables 1 and 2).
Discussion
In this study, we identified 2 neuroanatomic biotypes in pa-
tients with PD with otherwise similar demographics using an
unbiased data-driven clustering approach applied to the PPMI
cohort. Neuroanatomic biotypes differed in symptomatology
even at presentation before treatment and thereafter pro-
gressed at different rates. Themost striking baseline difference
was the much higher RBD Screening Questionnaire score in
biotype 1.
Our results provide support for 2 different neuroanatomic
phenotypes within patients with PD. Compared to healthy
controls, the neuroanatomic differences were more wide-
spread in patients with biotype 1, spanning across almost
all of the brain. Compared to patients with biotype 1, pa-
tients with biotype 2 had less widespread differences at
baseline.
Patients with biotype 2 had larger subcortical volume
(higher DBM values) than controls on average, suggesting
they may contain more cells (including dopaminergic cells)
and synapses, increasing the ability to support maintenance
of function despite declines in brain volume. Accordingly,
patients with biotype 2 had a slower disease progression
rate.3 In contrast, patients with biotype 1 had less brain
reserve and did not compensate as well as those with biotype
1 as PD progressed over time, resulting in a faster disease
progression rate. Indeed, there was evidence that this was
already the case at the time of presentation, given the worse
symptom severity in several domains in biotype 1 than in
biotype 2. In summary, we hypothesize that the different
rates of symptom progression relate to different brain
reserves.13,16
Figure 3 Dendrogram of the final hierarchical cluster solution of patients with PD in the PPMI patients
Matrix under the dendrogramshows the distance of
the neuroanatomic patterns between different pa-
tients with Parkinson disease (PD). Each element (i
row and j column) in the matrix indicates the dif-
ference of the neuroanatomic patterns between the
i participant and j participant. PPMI = Parkinson’s
Progression Markers Initiative.
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Brain reserve describes the differences in brain volume and
structure that may support maintenance of function despite
pathology.13,44 Gross or regional brain volume reflects the
quantity of neurons, neuronal integrity, and synaptic densities,
which determine the ability of the brain to engage in compen-
satory activity.13,44 Prior works have highlighted a link between
brain volume and markers of functional reserve in patients with
PD and other neurodegenerative diseases.14–16 For example,
there is a relationship between brain gray matter volume and
the magnitude of network-level integration.16 Basal forebrain
volume can predict future psychosis in early PD, and higher
cholinergic nucleus 4 gray matter density is associated with a
lower risk of reporting psychotic symptoms.17 PDwith cognitive
impairment shows lower gray matter volume in the nucleus
basalis of Meynert.20 Compared to tremor-dominant patients,
patients with PIGD had lower gray matter volumes in the globus
pallidus and amygdala and have worse prognosis with a more
rapid decline.45,46 In line with these observations, our results
suggest that a larger subcortical volume helps limit the nega-
tive impact of PD pathology during disease progression, as
Figure 4 Different neuroanatomic patterns in the 2 PD biotypes compared with healthy controls
Warm color indicates higher deformation-basedmorphometry (DBM) values in patients with Parkinson disease (PD); cold color indicates lower DBMvalues (p
< 0.005, false discovery rate correction). (A) The t values of comparison of DBM values between biotype 1 and controls. (B) The t values of comparison of DBM
values between biotype 2 and controls.
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Figure 5 Longitudinal changes in outcomes of interest in different biotypes of PD among the PPMI patients with 5 years of
follow-up
Asterisks indicate the statistical significance of the comparison between 2 biotypes in the clinical variables at the time of different follow up (A–F; *p < 0.05, **p
< 0.01, ***p < 0.005, uncorrected for multiple comparisons). The Parkinson’s Progression Markers Initiative (PPMI) data contain 1 baseline set of data and 12
follow-up sets of data over 5 years. PD = Parkinson disease; PIGD = postural instability and gait disorder; UPDRS = Unified Parkinson’s Disease Rating Scale.
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Table 2 Longitudinal motor and nonmotor score estimated β coefficients in different biotypes of PD with covariate
correction in the PPMI patients with 5 years of follow-up
Biotype 1 Biotype 2 t Value p Value
Total UPDRS score 5.32 (0.39) 3.4 (0.3) 3.92 <0.001
Motor symptoms and signs
UPDRS Part II score 1.49 (0.12) 0.81 (0.09) 4.5 <0.001
UPDRS Part III score 2.6 (0.25) 1.73 (0.19) 2.76 0.025
Tremor score 0.022 (0.008) 0.012 (0.006) 0.99 0.485
PIGD score 0.111 (0.011) 0.051 (0.009) 4.2 0.001
Schwab-England score −2.55 (0.24) −1.66 (0.18) −2.93 0.022
Nonmotor symptoms and signs
UPDRS Part I score 1.22 (0.1) 0.84 (0.08) 2.91 0.022
RBD Screening Questionnaire score 0.254 (0.057) 0.225 (0.043) 0.42 0.717
Epworth Sleepiness Scale score 0.572 (0.087) 0.384 (0.066) 1.71 0.223
Cognitive function
MOCA (adjusted) score −0.268 (0.07) −0.09 (0.053) −2.02 0.121
Benton Judgment of Line Orientation
score
−0.097 (0.042) −0.023 (0.032) −1.39 0.318
HVLT immediate total recall score −0.255 (0.101) 0.11 (0.077) −2.86 0.024
HVLT discrimination recognition
score
0.061 (0.041) 0.09 (0.031) −0.58 0.662
HVLT score −0.013 (0.005) 0.001 (0.004) −2.09 0.114
Letter-number sequencing score −0.258 (0.053) −0.09 (0.04) −2.54 0.044
Semantic fluency score −0.399 (0.198) 0.016 (0.15) −1.67 0.226
Symbol digit modalities score −1.228 (0.199) −0.4 (0.15) −3.32 0.008
SCOPA–Autonomic questionnaire
score
Gastrointestinal 0.409 (0.048) 0.28 (0.036) 2.15 0.106
Urinary question 0.271 (0.087) 0.217 (0.065) 0.49 0.708
Cardiovascular 0.096 (0.021) 0.085 (0.016) 0.43 0.717
Thermoregulatory 0.18 (0.035) 0.133 (0.027) 1.07 0.485
Pupillomotor 0.023 (0.015) 0.042 (0.011) −1.03 0.485
Sexual 0.302 (0.128) 0.431 (0.097) −0.8 0.582
Total score 1.269 (0.19) 1.194 (0.143) 0.32 0.776
Geriatric Depression Scale
score
0.17 (0.055) 0.112 (0.041) 0.85 0.572
STAI score 0.249 (0.343) 0.305 (0.259) −0.13 0.897
STAI state subscore −0.041 (0.191) 0.098 (0.144) −0.58 0.662
QUIP scores
GMB 0.005 (0.003) 0 (0.002) 1.44 0.314
Sex 0.012 (0.005) 0.008 (0.004) 0.67 0.662
Continued
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represented by brain atrophy. Physical exercise has been shown
to increase brain volume in older adults.47 Therefore, interven-
tions that increase physical activity before or in the early course
of PDmay contribute to brain reserve and help slow the rates of
disease progression.
At baseline, patients with biotype 1 had evidence of worse
behavioral, autonomic, andmotor impairment and, above all, of
worse RBD symptomatology. These findings are consistent
with past observations showing that motor dysfunction is as-
sociated with cognitive decline, autonomic dysfunction, and
RBD.28,48 PD with RBD is also associated with faster motor
progression and a higher risk of cognitive decline.28 In line with
these studies, we found that patients with biotype 1 had much
worse RBD symptomatology and more cognitive decline. RBD
may be a useful marker for early subtyping of PD at baseline.28
Patients with biotype 1 had significantly higher scores in several
motor disease symptoms after only 1 year of follow-up, but
there was no difference in the progression of tremor between
the 2 biotypes. This may reflect that rest tremor may be more
closely related to degeneration of nondopaminergic, rather
than dopaminergic, systems.49 In most cases, there is a sub-
stantial asymmetry of clinical symptoms from disease onset,
and patients with unilateral disease showed a significant dif-
ference in striatal uptake between the ipsilateral and contra-
lateral sides in both the caudate and putamen nuclei.49
Differences in longitudinal denervation between the left and
right caudate and putamen between the 2 biotypes (see data
available from Dryad, figure e-12, doi.org/10.5061/dryad.
xsj3tx9bf)may reflect different disease severity. Consistent with
previous findings that CSF biomarkers are not useful bio-
markers of PD progression,50 our results did not show signif-
icant differences in CSF biomarker levels between the 2
biotypes at baseline (table 1).
While the 2 identified neuroanatomic biotypes showed group
differences in terms of symptom severity and longitudinal
progression, there is overlap in the neuroanatomic features at
the individual level between the 2 biotypes. It is plausible that
some patients were a combination of >1 biotype, and this
would not be captured by our approach of discretizing bio-
types. Future research should further investigate more refined
biotype definitions based on continuous membership proba-
bility values through longitudinal studies in larger cohorts.
Therefore, we regard the 2 biotypes identified here as just an
initial solution to the problem of diagnostic heterogeneity in a
subtyping process that relies primarily on neuroanatomic
features correlated with clinical scores. It is likely that cohort
limitations (the PPMI patients on the whole have a higher
level of education, are younger, and have less baseline dis-
ability than the general PD population23), the size of our
cluster-discovery dataset, and the subjectivity of clinical-
symptom assessments were also limiting factors. For these
reasons, a novel cohort with longitudinal clinical data will be
useful for validating the present findings.
We show that neuroanatomic biotypes can be defined that
robustly predict different rates of progression, suggesting that
these reflect true biotypes of PD. Given that PPMI recruited
early patients from multiple sites, our results should still be
mostly generalizable to early PD in real clinical practice where
the findings can be used to inform estimates of prognosis.
These results might also have implications for clinical trial
design in early PD in the future. The existence of neuroana-
tomic biotypes that show specific trajectories of clinical score
decline may require biotype-specific outcome measures tai-
lored to the expected rate of decline in different domains.
We have robustly identified 2 different neuroanatomic bio-
types among patients with early PD using a data-driven
clustering approach. These biotypes showed distinct neuro-
anatomic patterns, symptoms, and rates of progression. Rec-
ognition of this heterogeneity is an important step toward
precision medicine for PD.
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